Transfusion Service Software Confirms its Leading Position in French Hospital Market with More Than 130 Installations
DENVER, Jan. 14 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced that its subsidiary, Inlog, has licensed its EgdeTrack* Transfusion Services Software (marketed as "Hemo Serveur" in France) to nineteen additional hospitals during the fourth quarter of 2008.
EdgeTrack Transfusion Management Software provides a complete transfusion record, including patient information, pre and post-transfusion data tracking, tracing of blood components and comprehensive tracking of orders, making it easier for hospital technicians to provide appropriate blood products for patients. EdgeTrack's complete feature set and configurability will assist each of these hospitals in meeting their diverse needs and improve their processes.
In Q4 of 2008, the following French healthcare organizations chose Inlog for their blood traceability and transfusion management: Hospices Civils de Lyon (4 hospitals), Polyclinique de la Ligne Bleue (Epinal), Vienne Hospital, Dreux Hospital, Centre Medical de Forcilles, Bourgoin Jallieu Hospital, Tarare Hospital, Laval Hospital, Villefranche-sur-Saone Hospital, CAPIO group (4 hospitals), Centre Anti-Cancer Paul Papin (Angers), Aubenas Hospital, Oyonnax Hospital. These hospitals join the 43 other establishments that chose EdgeTrack last year, including 21 Assistance Publique - Hopitaux de Paris ("AP-HP") hospitals, one of the largest healthcare information technology projects ever undertaken in Europe.
Since EdgeTrack was introduced into the market in 1995 as "Hemo Serveur", it has become a leading hospital transfusion and traceability information management system in France with more than 130 licensed hospitals. EdgeTrack easily connects with most laboratory information systems (LIS) and hospital information systems (HIS). EdgeTrack interchanges data with all major blood banking information systems including Inlog's own EdgeBlood (which is installed in 100% of the French Blood Establishment's "EFS" Blood Donor Centers).
Will Willman, Senior Vice President of Sales and Marketing EU/ME/Asia at Global Med Technologies, commented, "We are very pleased to have such wide French market acceptance of our transfusion software. EdgeTrack has been steadily gaining market share, which is now approximately 50% of the French public hospitals that have transfusion software installed. EdgeTrack has become a de-facto standard for French public hospitals that require a proven transfusion solution with quality installation, training and support services. We look forward to helping each of these hospitals continue to provide excellent and advanced transfusion services to their physicians and patients."
About Global Med Technologies, Inc.
Global Med Technologies(R), Inc. is an international medical software company which develops regulated and non-regulated products and services for the healthcare industry. As a leading provider of blood and laboratory systems and services, Global Med's products are deployed in 20 countries and serve over 1,600 transfusion centers, blood banks and laboratories.
Global Med's domestic companies are Wyndgate Technologies(R), a leader in software products and services for donor centers and hospital transfusion services; eDonor(R), which offers web-based donor relationship management systems; and PeopleMed(TM), Inc., which implements cost-effective software validation, consulting and compliance solutions to hospitals and donor centers.
Global Med's European subsidiary, Inlog, SA, is a leading developer of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally.
For more information about Global Med's products and services, please call 800-996-3428 or visit www.globalmedtech.com.
This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.
|SOURCE Global Med Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved